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Abstract 
C/EBPα (p42 and p30 isoforms) is commonly dysregulated in cancer via the action of oncogenes, 
and specifically in acute myeloid leukaemia (AML) by mutation. Elevated TRIB2 leads to the 
degradation of C/EBPα p42, leaving p30 intact in AML. Whether this relationship is a cooperative 
event in AML transformation is not known and the molecular mechanism involved remains elusive. 
Using mouse genetics our data reveal that in the complete absence of C/EBPα TRIB2 was unable to 
induce AML. Only in the presence of C/EBPα p42 and p30 were TRIB2 and p30 able to cooperate to 
decrease the latency of disease. We demonstrate the molecular mechanism involved in degradation of 
C/EBPα p42 requires site-specific direct interaction between TRIB2 and C/EBPα p42 for the K48-
specific ubiquitin-dependent proteasomal degradation of C/EBPα p42. This interaction and 
ubiquitination is dependent on a critical C-terminal lysine residue on C/EBPα. We show effective 
targeting of this pathway pharmacologically using proteasome inhibitors in TRIB2 positive AML 
cells. Together, our data show that excess p30 cooperated with TRIB2 only in the presence of p42 to 
accelerate AML and the direct interaction and degradation of C/EBPα p42 is required for TRIB2-
mediated AML.  
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Introduction 
The C/EBPα (CCAAT/enhancer binding protein α) transcription factor is commonly mutated in acute 
myeloid leukaemia (AML) and dysregulated in a number of cancers (i.e. liver, prostate, lung, 
squamous cell carcinoma). Mutations in CEBPA occur exclusively in haematological diseases and 
result in perturbed C/EBPα protein expression and function. C/EBPα promoter methylation perturbs 
C/EBPα expression in AML(1), CML(2), and head and neck squamous cell carcinoma(3). In AML, 
oncogene-mediated dysregulation of C/EBPα mRNA expression and/or protein activity occurs in 
cytogenetically abnormal subtypes of AML, including AMLs with t(8;21)[AML1-ETO], 
inv(16)[CBFb-MYH11], t(15;17)[PML-RARA], and t(3;21)(AML-1-MDS-1-Evi-1 fusion protein) 
translocations, and in cytogenetically normal (CN)-AMLs with FLT3-ITD mutation, or with elevated 
TRIB2 expression(4). C/EBPα protein is also dysregulated by a number of posttranslational 
modifications including phosphorylation, sumoylation and ubiquitination(5).  
CEBPA is an intronless gene with N-terminal transcriptional activation domains and a C-terminal 
basic region leucine zipper (LZ) domain. CEBPA mutations, which occur across the entire coding 
region, are present in 5% and 10% of childhood and adult AML respectively(6). Somatic and 
inherited mutations in CEBPA co-occur, are often bi-allelic, and are found with higher frequency in 
cytogenetically normal (CN) AML(7,8). CEBPA is a favourable prognosis factor in AML, 
specifically for cases that present with double mutations in CEBPA, typically an N-terminal and a C-
terminal basic region LZ gene mutation. C/EBPα protein exists as two isoforms, a full length C/EBPα 
p42 isoform classified as a tumour suppressor, and an N-terminally truncated p30 isoform classified 
as an oncogene. N-terminal mutations typically are frame-shift mutations that lead to a premature stop 
in translation of p42, while retaining p30 expression. In contrast, C-terminal mutations typically are 
in-frame insertions/deletions in the LZ domain that disrupt DNA binding or dimerization. C/EBPα 
functions by forming stable homo-and heterodimers with itself and other C/EBP family members, 
which act to stabilize their protein expression(9).  
TRIB2 is a potent oncogene capable of inducing fully penetrant AML in murine models, and can 
cooperate with other AML oncogenes to disrupt signaling pathways and transcription factors in AML 
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disease(10-13). TRIB2 expression was shown to be elevated in a cohort of AML patients with a 
mixed myeloid/lymphoid phenotype and a dysregulated CEBPA gene expression signature. In fact, 
TRIB2 leads to the degradation of C/EBPα p42 via E3 ligase COP1 binding whilst sparing p30 from 
degradation, resulting in disturbed granulopoiesis. This modulation of C/EBPα was found to be 
critical for the induction of AML in vivo(10,13). E2F1 cooperates with C/EBPα p30 to activate the 
Trib2 promoter in preleukaemic cells resulting in elevated TRIB2 expression. This was shown to be 
an important mechanism regulating TRIB2 expression and survival of AML cells(12). 
In normal cells, C/EBPα is a key transcription factor in the transition from the pre-granulocyte-
macrophage (pre-GM) to the granulocyte-macrophage progenitor (GMP) stage of differentiation, and 
in the transcriptional and epigenetic control of haematopoietic stem cell (HSC) self-renewal(14-16). 
In GMP progenitor cells, C/EBPα p42 is found bound to the Trib2 promoter and inhibits E2F1-
mediated activation of Trib2. At the HSC stage, C/EBPα acts to prime HSCs for differentiation along 
the myeloid lineage via DNA binding to regulatory regions of genes induced during 
differentiation(16). Although conditional Cebpa knockout mice do not develop disease, the loss of 
Cebpa in adult HSCs leads to an increased number of functional and proliferative HSCs(15,17) and 
loss of HSC pool maintenance in serial transplantations(16). Cebpa expression is required for AML 
disease initiation by the oncogene MLL-ENL but not for disease maintenance(18). In contrast, Cebpa 
is required for the maintenance of Hoxa9/Meis1 AML disease(19). Loss of Cebpa did not abrogate 
BCR/ABL induced leukaemia but it did alter the resultant disease phenotype(20). Thus, it appears that 
a certain threshold of C/EBPα expression is important for the development of myeloid leukaemic 
disease. This is supported by the observation that leukaemia-derived CEBPA mutations are virtually 
never null mutations(21,22). The combination of N- and C-terminal mutations have distinct features 
that result in leukaemia development(23,24). Murine knockin studies investigating p30 oncogenicity 
in the absence of C/EBPα p42 showed that p30 induced fully penetrant transplantable AML(25). p30 
is sufficient for haematopoietic commitment to the myeloid lineage, it enables transition from the 
common myeloid progenitor (CMP) to the GMP stage. However it does not retain the ability to 
control proliferation and myeloid progenitors have greatly increased self renewal capacities(25). 
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While TRIB2 disrupts the ratio of C/EBPα p42:p30 and functions to degrade C/EBPα, it is unclear 
whether the loss of C/EBPα p42, or the expression of C/EBPα p30 is critical for TRIB2 mediated 
AML disease. Here we show using mouse genetics that the presence of C/EBPα is paradoxically 
required for TRIB2 induced AML, and only in the presence of C/EBPα p42 is there a cooperative 
effect seen with TRIB2 and C/EBPα p30. We dissect the molecular details of the degradative 
relationship between TRIB2 and C/EBPα p42, and show that the direct interaction between TRIB2 
and C/EBPα p42 is required for TRIB2-mediated ubiquitin-dependent proteasomal degradation of 
C/EBPα p42. We identify lysine 313 of C/EBPα as a site of TRIB2-mediated ubiquitination. We 
show that we can target TRIB2 AML cells with proteasome inhibition. Together, these data show that 
C/EBPα presence is required for the initiation of TRIB2 induced AML and subsequent C/EBPα 
p42/p30 disruption is critical for TRIB2 AML disease. 
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Results 
C/EBPα p42 accelerates AML in the presence of TRIB2 and excess p30 
In order to establish if C/EBPα is essential for TRIB2-induced AML, we performed a bone 
marrow transplant using a previously described conditional Cebpafl/fl; Mx1Cre mouse model and used 
polyinosinic-polycytidylic acid (pIpC) to facilitate ablation of C/EBPα in the haematopoietic 
compartment. Two weeks post deletion, c-Kit+ haematopoietic stem and progenitor cells (HSPCs) 
from the BM of pIpC treated control Cebpafl/fl and Cebpa∆/∆ animals were transduced with either 
empty MigR1 or MigR1-TRIB2 retrovirus. Transduced cells were transplanted into irradiated 
recipients, and monitored for disease progression. As expected, all mice reconstituted with Cebpafl/fl 
cells expressing TRIB2 developed lethal AML with a median latency of 33 weeks, accompanied by 
accumulation of GFP+ cells (mean fraction of Cebpafl/fl GFP-expressing cells 93% +/- 5.2%) in the 
bone marrow and splenomegaly (data not shown). In striking contrast, TRIB2 transduced Cebpa∆/∆ 
HSPCs did not give rise to AML (Fig. 1A and supplemental fig. 1B). Notably, 14 months after 
transplantation CD45.2+GFP+ cells were detected suggesting that the TRIB2 expressing Cebpa∆/∆ cells 
are able to properly home to the bone marrow but do not give rise to leukaemia. Therefore, while 
TRIB2 functions to degrade C/EBPα p42 leading to AML(10), the complete absence of C/EBPα 
abrogates TRIB2 oncogenicity. Thus, it appears that a certain threshold of C/EBPα (p42 or p30) 
expression is necessary for the initiation of TRIB2 AML. 
Having established the necessity of C/EBPα expression for TRIB2 AML, we next sought to 
elucidate whether p42 degradation or p30 accumulation is the key driver of this pathway, and whether 
p30 can cooperate with TRIB2 to accelerate disease onset. In order to investigate this we designed a 
transplant model which utilised donor cells from an established Cebpa conditional knockout model 
that only expressed p30 isoform (referred to here as Cebpa∆/p30), or were heterozygous for this allele 
still expressing p42 on one allele (referred to as Cebpafl/p30 cells) (See methods and Fig. 1B). CD45.2+ 
donor cells from pIpC treated 8-14 week old Cebpafl/+, Cebpafl/p30 and Cebpafl/p30; Mx1Cre mice were 
harvested two weeks post deletion, transduced with MigR1 or MigR1-TRIB2 retrovirus and 
transplanted into CD45.1+ recipients. CD45.2 and GFP expression were monitored at 7 weeks post-
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transplant in peripheral blood (supplementary fig. 1C-D) and every 2 weeks thereafter, showing 
recipient reconstitution with donor cells. The cohort of mice transplanted with TRIB2 transduced 
Cebpafl/+ cells developed AML disease as previously published(10) with a median latency of 49 
weeks. However, mice transplanted with TRIB2 transduced Cebpafl/p30 cells developed a much more 
aggressive AML with an accelerated latency of 29 weeks (Fig. 1C) as evidenced by accumulation of 
GFP+ cells in the bone marrow, elevated white blood cell counts and splenomegaly (supplemental fig. 
1E-J). Mice transplanted with MigR1 transduced Cebpa∆/p30 cells developed AML with a median 
latency of 40 weeks, as expected and previously published for CebpaL/L mice(25)(“L” refers to p30), 
and no significant acceleration of the disease was seen in mice transplanted with TRIB2 transduced 
Cebpa∆/p30 cells (median latency of 35 weeks) (Fig. 1D). Comparing TRIB2-AML in Cebpafl/p30 and 
Cebpa∆/p30 cohorts, p42 accelerated AML in the presence of TRIB2 and excess p30 (Fig. 1E). Control 
cohorts of mice transplanted with Cebpafl/p30 and Cebpafl/+ cells transduced with MigR1 as expected 
did not develop any disease. Flow cytometry analysis showed that mice in both of these groups had 
normal haematopoietic compartments (supplemental fig. 1E-I). Flow cytometry analysis revealed that 
the leukaemic profile of GFP+ Cebpafl/+-TRIB2, Cebpafl/p30-TRIB2, Cebpa∆/p30-TRIB2 and Cebpa∆/p30-
MigR1 AML cells was predominantly c-Kit+ (Fig. 1F). Protein analysis of the leukaemic bone 
marrow cells between the GFP+ Cebpafl/+-TRIB2, Cebpafl/p30-TRIB2, Cebpa∆/p30-TRIB2 and 
Cebpa∆/p30-MigR1 AML cells groups verified expected p42 and p30 expression levels in mice 
(leukaemic ratio p42:p30 in Cebpafl/+-TRIB2 cohort, p42 and increased p30 in Cebpafl/p30-TRIB2 and 
Cebpafl/p30-MigR1 cohort, comparable p30 in the absence of p42 in Cebpa∆/p30-MigR1 and Cebpa∆/p30-
TRIB2 cohorts (Fig. 1G). Taken together these data show that despite TRIB2 functioning to degrade 
p42, C/EBPα is essential for the initiation of TRIB2 mediated AML and only in the presence of 
C/EBPα p42 is there a cooperative effect seen with p30.  
Identification of specific amino acids involved in the TRIB2 and C/EBPα interaction  
Having shown the requirement for C/EBPα p42 in the initiation of TRIB2-induced AML we next 
focused on the interaction between C/EBPα and TRIB2. We first determined using subcellular 
fractionation and confocal microscopy that the co-localisation of TRIB2-C/EBPα was nuclear 
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(supplementary fig. 2A and B). Using GST pull-down experiments we show that the C-terminal 
leucine zipper (LZ) domain of C/EBPα is required for the interaction with TRIB2 as a GZ mutant 
expressing an unrelated LZ could no longer bind TRIB2. However, TRIB2 can still bind a C/EBPα 
LZ mutant (L12V) that can no longer dimerise, indicating TRIB2 binding to C/EBPα is independent 
of amino acids involved in C/EBPα dimerization (supplementary Fig. 2C, D and E). To more 
precisely identify specific regions of interaction with TRIB2, we SPOT-synthesized a peptide array 
containing a series of 18-amino acid overlapping peptides identical to the C-terminus LZ domain of 
C/EBPα. GST-TRIB2 bound to eight peptides within the C-terminus LZ of C/EBPα (Fig. 2A). To 
identify the specific amino acids required for the interaction, we used a Specific Alanine Scanning 
Substitution Array (SASSA), where consecutive amino acids of the parent peptides were substituted 
to an Alanine. This identified residues R333, R339 and R343 of C/EBPα as potential mediators of 
interaction with TRIB2 (Fig. 2B). Using site-directed mutagenesis (SDM) we show that mutation of 
R339A abolished the interaction with GST-TRIB2 in a pull-down assay (Fig. 2C). This was 
confirmed by co-immunoprecipitation in mammalian cells (supplementary fig. 2F) indicating that 
R339 of C/EBPα is required for interaction with TRIB2.  
Reciprocally, we used TRIB2 peptide arrays that covered the entire TRIB2 protein to identify 
specific amino acids in TRIB2 responsible for the interaction with C/EBPα. Recombinant C/EBPα 
protein bound to peptides that spanned from amino acids 25-318 indicating extensive interaction of 
C/EBPα with TRIB2 (Fig. 3A). SASSA of amino acids in peptide 2 (DHVFRAVLHSHGEELVCK) 
identified R77, which is homologous to R107 in TRIB1 that exists as a gain of function TRIB1 
mutation in AML(26). SASSA of amino acids in peptide 4 (PEILNTSGSYSGKAADVW) identified a 
putative GSK3 phosphorylation site (which has the consensus GSK3 phosphorylation site motif 
S/TXXXS/T). SASSA of peptide 5 (HPWFSTDFSVSNSGFGAK) identified K322 (Fig. 3B). Three 
mutants R77A, S227A/S229A/S231A/K233A (4-AA) and K322A were generated (Fig. 3C). Co-
immunoprecipitation showed that mutation of the sequence S227A/S229A/S231A/K233A (4-AA) 
abolished the interaction with C/EBPα completely, and K322A and R77A while reduced could still 
bind C/EBPα (Fig. 3D and supplementary Fig. 2G).  
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Ubiquitin-mediated mechanism of TRIB2-induced p42 degradation 
We next assessed the ability of TRIB2 to induce ubiquitin specific degradation of C/EBPα. A 
ubiquitination assay was performed in 293T cells transfected with C/EBPα, TRIB2 and Ubiquitin 
(Ub). Increased C/EBPα ubiquitination was observed in TRIB2 expressing cells compared to controls 
and this was exclusively K48 mediated ubiquitination (proteasome degradation K48 specific 
polychains as opposed to non-degradative ubiquitination mediated by K63 polychains) as detected by 
K48 and K63 specific antibodies (Fig. 4A). This was confirmed using ubiquitin mutants which do not 
express the K48 ubiquitin polychain (UB/K48R-HA) and the K63 ubiquitin polychain (UB/K63R-
HA) in a ubiquitination assay (Fig. 4B compare lanes 7, 8 and 9). We show using the R339A C/EBPα 
binding mutant that the direct binding between TRIB2 and C/EBPα was required for TRIB2-mediated 
ubiquitination of C/EBPα compared to the control mutant R343A that retains the TRIB2 interaction 
(Fig. 4C). Reciprocally, using the TRIB2 binding mutant S227A/S229A/S231A/K233A (4-AA) 
revealed a loss in C/EBPα ubiquitination as compared to the mutants R77A and K322A that retain 
higher C/EBPα binding affinity or WT TRIB2 (Fig. 4D). Together these data show that the direct 
binding interaction between TRIB2 and C/EBPα was required for TRIB2-mediated ubiquitination of 
C/EBPα. 
To investigate the site on C/EBPα susceptible to TRIB2 mediated ubiquitination, Ubpred online 
software analysis of C/EBPα was performed and identified a number of lysine residues as potential 
ubiquitination sites with low to high confidence scores. K313 was predicted with medium confidence 
as a potential ubiquitination site (Fig. 5A and B) which has been identified as a recurrent C/EBPα 
mutation (K313dup) that results in an extra lysine adjacent to K313. This duplication occurs in 10% 
of C/EBPα mutated AMLs and identified to have a shorter protein half-life than wildtype C/EBPα as 
determined by cycloheximide assay(27). Mutation of K313 to K313R resulted in the loss of TRIB2-
induced C/EBPα ubiquitination as compared to WT C/EBPα (Fig. 5C). As a control we show that this 
mutation retains functional C/EBPα transcriptional activity as both WT and mutant C/EBPα 
stimulated the G-CSFR luciferase reporter construct, a known C/EBPα target gene (Fig. 5D). These 
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data show that K313 serves as the site of ubiquitin conjugation on C/EBPα in the presence of TRIB2 
and mutation of K313 abrogates TRIB2-mediated ubiquitin-dependent proteasomal degradation of 
C/EBPα. This site is also present in p30 yet we do not observe TRIB2-mediated p30 ubiquitination 
(Fig. 5E), suggesting that perhaps the N terminus of C/EBPα p42 functions in the degradative 
complex.  
Proteasome Inhibition selectively targets AML with high TRIB2 expression 
Our data suggest that inhibition of the proteasome would effectively inhibit the function of TRIB2 
by abrogating C/EBPα protein degradation and would be an effective pharmacological targeting 
strategy in TRIB2 positive AMLs. To test this U937 cells (express detectable levels of endogenous 
TRIB2 and C/EBPα) transduced with retroviral MigR1-GFP control and MigR1-TRIB2-GFP were 
treated with 10 nM bortezomib (a reversible inhibitor of the proteasome chymotryptic activity 
resulting in the accumulation of K48 ubiquitin linked proteins). An increase in cytotoxicity in the 
TRIB2 overexpressing cells compared to MigR1 control transduced cells was observed and cells 
expressing TRIB2-VPM that cannot degrade C/EBPα behaved similarly to control cells (Fig. 6A 
panel 1 and 2). Overexpression of MigR1-C/EBPα was able to rescue bortezomib induced cell death 
in U937 cells (Fig. 6A panel 3). In C/EBPα negative leukaemia cells, K562 and Kasumi 1 bortezomib 
toxicity was not increased following TRIB2 overexpression supporting the specificity of bortezomib 
on the TRIB2-C/EBPα axis (Fig. 6A panel 4 and 5). Second generation irreversible proteasome 
inhibitors(28,29) also showed selective killing of high TRIB2 (lentiviral Phr-GFP) expressing AML 
cells as assessed by cell viability (Fig. 6B). Bortezomib treatment rescued the degradation of C/EBPα 
p42 seen with TRIB2 overexpression in U937 cells (Fig. 6C). In fact, p30 expression remains upon 
TRIB2 overexpression, confirming our ubiquitination data in figure 5. We next established a human 
AML orthotopic xenograft model in which U937 cells were propagated in NSG xenografts and mice 
were either treated with bortezomib in vivo (Fig. 6D and described in methods), or TRIB2 was 
knocked down using shRNA lentivirus (Fig. 6E(12)). In vivo bortezomib treatment significantly 
impaired the engraftment of U937 cells as determined by lower % of engrafting GFP+ cells positive 
for human antibody CD45 expression (Fig. 6F). Additionally, engraftment of U937 cells expressing 
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shTRIB2 lentivirus in NSG xenografts showed that in comparison to control (shctrl), knockdown of 
TRIB2 impaired the progression of U937 orthotopic xenografts (Fig. 6G). Together our data show 
that TRIB2 expressing AML cells can be pharmacologically targeted with proteasome inhibition due, 
in part, to inhibition of the TRIB2 proteolytic function on C/EBPα.   
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Discussion 
Although C/EBPα dysfunction is a common occurrence in different cancers, details on the 
mechanisms involved in bringing about the loss of C/EBPα protein expression in Cebpa wild type 
and mutated AML are yet to be fully elucidated. In this study we identify the molecular mechanism 
involved in the dysregulation of C/EBPα expression via TRIB2 in AML. We and others(10,13,30) 
have previously demonstrated that TRIB2 overexpression induces AML and that it degrades C/EBPα 
p42. Here we provide novel insights on this process and show that the presence of C/EBPα p42 is 
required not only to initiate TRIB2 AML, but also for TRIB2 to cooperate with C/EBPα (p42 loss and 
increased p30) in driving AML disease. Our data support the emerging notion that C/EBPα functions 
in the initial transformation, as supported by the data showing that C/EBPα regulated a transcriptional 
program essential for initiation yet dispensable for the maintenance of MLL-ENL disease(18). Our 
data clearly show loss of C/EBPα p42 via TRIB2 induced ubiquitin-mediated degradation and excess 
p30 expression cooperates to accelerate AML.  
Using bone marrow transduction and transplantation approaches we show that C/EBPα p42 
isoform expression from one Cebpa allele is necessary and sufficient for TRIB2 to cooperate with p30 
isoform in AML. The addition of TRIB2 does not further accelerate AML induced by excess p30 
itself, but does accelerate AML when p42 is present. This suggests that p30 is necessary for TRIB2-
mediated AML induction. The possibility remains that TRIB2 may convert p42 to p30 to form 
additional p30 protein but we have not any evidence for this here. Under normal physiological 
conditions the protein levels of C/EBPα p42 are greater than p30 protein levels, and when this 
balances changes toward more p30 levels it is considered “leukaemic”, as observed in leukaemic cell 
lines and AML patients(22). We showed K313 in the C terminus of C/EBPα p42 was critical for 
TRIB2-mediated ubiquitination and proteasomal degradation. This lysine residue is a common 
mutation in AML patients (~10% of all C/EBPα mutations) which results in the duplication of the 
single lysine to KK leading to reduced protein stability(27). Using mouse genetics it was shown that 
this duplication of K313 to K313KK (K313dup) resulted in an increased proliferation of long-term 
HSCs (LT-HSCs) leading to an expansion of premaligant HSCs not seen with the N-terminal 
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mutations(23). Our data show that the absence of this lysine by mutation to an arginine (K313R) 
abrogates the susceptibility of C/EBPα to degradation whilst retaining its DNA binding and 
transcriptional activation function. This suggests that TRIB2 degrades C/EBPα p42 via ubiquitination 
of K313 and duplication of this residue as occurs in AML patients samples would lead to an increase 
in C/EBPα p42 degradation in the presence of TRIB2. Patients with K313dup had TCR 
rearrangements and CD7 expression(27), lymphoid features associated with unfavourable outcome 
and which we have previously linked with TRIB2 and C/EBPα perturbation(31). Previous 
investigation of the combination of a C-terminal mutation (K313 duplication) with C/EBPα p30 
expression revealed co-operation and provides a possible explanation for the high prevalence of one 
N-term mutation and one C-term mutation in ~90% of biallelic C/EBPα mutant AMLs(23). We 
propose that the K313dup mutation in patients contributes to leukaemic transformation by increasing 
the susceptibility of C/EBPα to ubiquitination resulting in increased degradation of C/EBPα p42. A 
thorough investigation of TRIB2 function in K313 mutant patient cells would further validate this.  
C/EBPα p42 R339 and K313 amino acids are both present in p30 yet TRIB2 does not degrade 
p30. One explanation may be that the protein complexes containing TRIB2 and C/EBPα p42 or 
TRIB2 and p30 are different. Our previous work showed that TRIB2 binds with COP1 E3 ligase and 
this interaction is necessary for C/EBPα p42 degradation(13). While our peptide mapping clearly 
shows specific sites in both TRIB2 and C/EBPα responsible for the direct interaction, in the absence 
of crystal structure information we cannot predict further based on our data the reason why p30 is not 
targeted by TRIB2 for degradation. Our data does not discount a role for p30 in TRIB2 mediated 
AML; p30 presence may, for example, activate a unique set of genes, inhibit other C/EBPs or bind to 
a unique set of proteins distinct from C/EBPα p42 as previously reported(32,33). Indeed, U937 cells 
express endogenous C/EBPα but are less sensitive to bortezomib induced killing compared to TRIB2 
overexpressing cells. This suggests that TRIB2 must be affecting something in addition to C/EBPα 
p42 degradation to provide synergy in AML. Our data support further investigations into the 
proteomic profiling of AML, with a focus on the involvement of C/EBPα ubiquitination and the need 
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for an in-depth understanding of the C/EBPα ubiquitin regulatory pathway in normal versus 
leukaemic (CEBPA WT and mutant) settings. 
Whilst TRIB2 itself is an oncogene capable of driving AML, the molecular interaction identified 
here between TRIB2 and C/EBPα leading to dysregulated C/EBPα may have implications in other 
models of AML and indeed other cancers. It is clear that the loss of C/EBPα function is a common 
occurrence in a number of different cancer types. What is not clear at this point is the extent of the 
involvement of TRIB2 function across different haematological malignancies and other cancers. To 
date, cooperation between TRIB proteins and other oncogenes in AML has been demonstrated, most 
often with Hoxa9 and Meis1, suggesting that TRIB2 protein function downstream of commonly 
occurring oncogenic events may impact on C/EBPα(34,35). TRIB2 is found elevated in lung cancer 
and associated with the E3 ligase TRIM21(30). In liver cancer cells, TRIB2 associated with other E3 
ligases including β-TrCP, COP1 and Smurf1(36). Thus, there is a strong link between TRIB2 and the 
ubiquitin-proteasome system (UPS) in cancer.  
As shown here, high TRIB2 expressing cells are sensitive to bortezomib induced cellular toxicity. 
However, inhibition of the proteasome also targets other proteins, E3 ligases and their substrates. We 
currently have limited knowledge of TRIB2 degradation substrates in general, and indeed knowledge 
of TRIB2 as a substrate itself of the UPS in cancer. This study highlights the important molecular 
interplay between TRIB2 and C/EBPα in driving AML, and provides a framework for further 
investigations into targeting the UPS as an emerging cancer therapy.  
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Materials and Methods 
Murine Bone Marrow Transduction and Transplantation 
Cebpafl/fl; Mx1cre were crossed to Cebpa+/p30 ((25)p30 referred to as “L” allele previously) to yield 
Cebpafl/+; Mx1Cre, Cebpafl/p30; Mx1cre, Cebpafl/+ and Cebpafl/p30. Genotyping and evaluation of 
Cebpa excision methods provided in SI. 8-14 week old Cebpafl/fl, Cebpafl/fl; Mx1Cre, Cebpafl/+, 
Cebpafl/p30 and Cebpafl/p30; Mx1Cre mice were polyinosinic-polycytidylic acid (pIpC) treated (3 
injections every second day with 300 ug pIpC) to excise the Cebpa allele. Resultant genotypes are 
Cebpafl/fl (expressing solely p42 alleles which can give rise to p30), Cebpa∆/∆ (null for p42 and p30), 
Cebpafl/+ (expressing solely p42 alleles which can give rise to p30), Cebpafl/p30 (expressing one p42 
and one solely p30 allele), and Cebpafl/p30; Mx1Cre (referred to as Cebpa∆/p30, solely expressing one 
p30 allele) (Fig. 1B). Two weeks post deletion, CD45.2+ BM cells were collected and either c-Kit 
purified by magnetic-activated cell sorting (Fig. 1A), or total bone marrow (Fig. 1C-D) was 
transduced with 40% titre matched retrovirus in the presence of IL3, IL6 and SCF. Freshly transduced 
unsorted cells (1x106 Fig. 1A, 3x106 Fig. 1C) were injected by tail vein into lethally irradiated 
CD45.1+ recipients generating Cebpafl/fl -TRIB2 (n=12), CebpaΔ/Δ-TRIB2 (n=10), Cebpafl/+-MigR1 
(n=9), Cebpafl/+-TRIB2 (n=4), Cebpafl/p30-MigR1 (n=6), Cebpafl/p30-TRIB2 (n=8), Cebpa∆/p30-MigR1 
(n=6), Cebpa∆/p30-TRIB2 (n=8). Mice were monitored for 14 months and euthanized when they 
developed physical signs of disease (behavioural changes, laboured breathing, hunched posture) or 
high white blood cell counts. For NOD-SCID IL2Rγnull (NSG) mice Xenograft transplantation, 1x106 
U937 cells transduced with shTRIB2-GFP (n=5) or shCtrl-GFP (N=8) were transplanted into non-
irradiated NSG mice via tail vein injection. To assess bortezomib in vivo efficacy, GFP ctrl 
transduced U937 cells were injected and 5 days post injection mice were randomized and treated with 
either bortezomib (0.5mg/kg, n=3) or PBS (i.p. administration, n=3) at days 5, 7 and 11 post-
transplant which was well tolerated. Mice were sacrificed on day 16. Animals were maintained at the 
University of Copenhagen and the University of Glasgow, housed in accordance with their respective 
institutional guidelines. All work was carried out under the approval of the Danish Ethical Committee 
and the Home Office of the United Kingdom. 
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Flow Cytometry 
Cell suspensions were stained on ice in FACS Buffer (PBS ph7.0, 10mM Hepes, 0.02% sodium 
azide, 0.2% BSA). Analytical flow cytometry was performed on a FACS Canto (Becton Dickinson), 
sorting was performed on a FACS Aria II (Becton Dickinson) and data was analyzed using FlowJo 
software (Treestar, Version 10). Dead cells were excluded using DAPI and doublets excluded based 
on FSC-H and FSC-A. For apoptosis assays, Annexin V-PE (BD Biosciences 556422) or Annexin V-
APC (BD Biosciences 550475) was used.  
Details of vectors, antibodies, cell culture/transfections and real-time PCR provided in 
supplementary information (SI). 
Ubiquitination Assay, Co-Immunoprecipitation and Western Blotting. 
293T cells transfected with described vectors were treated with 10μM MG-132 five hours prior to 
lysis where indicated. For ubiquitination assay, cells were lysed in 1% SDS, sonicated and 
supernatants precleared with Protein G Sepharose 4 fast flow beads (GE healthcare) then incubated 
with C/EBPα antibody overnight. For Co-Immunoprecipitation (CO-IP), cells were lysed in Tris 
buffer (50mM Tris pH 7.4, 150 mM NaCl, 1mM EDTA, 0.5% NP-40, 5% glycerol, with protease and 
phosphatase inhibitors) and precleared lysates were incubated with C/EBPα antibody overnight. 
Whole cell proteins were isolated by RIPA lysis buffer (50mM Tris, pH 8.0, containing 0.5% NP-40, 
0.25% sodium deoxycholate, 150mM NaCl, 1mM EDTA, 20mM N-Ethylmaleimide with protease 
and phosphatase inhibitors) or by direct lysis (2X SDS sample buffer). Details of antibodies provided 
in SI. For GST-IP, 3mg of indicated cell lysate was added to 50μL of GSH slurry with pull down 
performed using 25ug of GST or GST-TRIB2 (Details of GST protein production provided in SI). 
Densitometric analysis of bands was carried out with ImageJ Software. n≥3 for all CO-IP and 
ubiquitination assays. 
Spot synthesis of peptides and overlay analysis.  
Peptide arrays were performed as previously described(37,38) (n=2) and details provided in SI. 
Briefly, peptide arrays encompassing the C-terminus of C/EBPα and the entire TRIB2 protein were 
generated and incubated with GST-TRIB2 or purified C-teminal C/EBPα (Genway). Arrays were 
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incubated with secondary antibodies and bound protein detected using ECL or the Odyssey® Infrared 
Imaging System (LI-COR Biosciences).  
Statistical analysis 
Statisitcal analysis and graphing was performed on GraphPad Prism (version 5.03). When comparing 
2 groups an unpaired, two-tailed Student’s t-test was used. The Log-rank test was used to compare 
groups on a survival curves. Statistical significance was attained when the P value ≤0.05 and was 
indicated in the related figure legends and graphs. 
 
  
18 
 
The authors declare no conflict of interest 
 
Acknowledgements 
We thank all the technical staff at the Paul O’Gorman Leukaemia Research Centre. We thank the 
Cancer Research UK Glasgow Centre (C596/A18076) and the Biological Service Unit facilities at the 
Cancer Research UK Beatson Institute (C596/A17196) and the Biological Services at the University 
of Glasgow. We thank Ruaidhrí Carmody for reagents and critical review of the work. We thank the 
Kay Kendall foundation (KKL501), and the Howat foundation for Flow cytometry facility funding. 
Work in the Keeshan lab was supported by the Howat Foundation and Children with Cancer UK. 
CO’C was supported by Childrens Leukaemia Research Project grant. PK was supported by Science 
Foundation Ireland Infrastructure award and the Mid-Western Cancer Foundation. Work in the Porse 
lab was supported by a centre grant from the NovoNordisk Foundation (The Novo Nordisk 
Foundation Section for Stem Cell Biology in Human Disease). 
 
Authorship Contributions 
Contribution: KK designed the study. FL, CO’C, CF, EO, MS and JC performed the research. BP 
provided transgenic mouse models. BP, PK, RL, RA and MC provided essential reagents and 
expertise. KK, FL, CO’C, MS, EO and JC analysed the data. CO’C and FL made the figures. KK 
wrote the paper. All authors edited the paper.  
 
  
19 
 
References 
1. Fasan A, Alpermann T, Haferlach C, Grossmann V, Roller A, Kohlmann A, et al. PLOS ONE: 
Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation 
in Normal Karyotype AML: A Study on 623 Cases. PLoS ONE. 2013;8(2):e54365.  
2. Annamaneni S, Kagita S, Gorre M, Digumarti RR, Satti V, Battini MR. Methylation status of 
CEBPAgene promoter in chronic myeloid leukemia. hem.  Maney Publishing; 2014 
Jan;19(1):42–4.  
3. Bennett KL, Hackanson B, Smith LT, Morrison CD, Lang JC, Schuller DE, et al. Tumor 
Suppressor Activity of CCAAT/Enhancer Binding Protein   Is Epigenetically Down-regulated 
in Head and Neck Squamous Cell Carcinoma. Cancer Research. 2007 May 15;67(10):4657–
64.  
4. Paz-Priel I, Friedman A. C/EBPalpha dysregulation in AML and ALL. Crit Rev Oncog. 
2011;16(1-2):93–102.  
5. Friedman AD. C/EBPα in normal and malignant myelopoiesis. Int J Hematol. 2015 Mar 10.  
6. Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CAJ, Wouters BJ, et al. 
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with 
CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence 
for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011 Feb 
24;117(8):2469–75.  
7. Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU. Somatic CEBPA Mutations Are a 
Frequent Second Event in Families With Germline CEBPA Mutations and Familial Acute 
Myeloid Leukemia. Journal of Clinical Oncology. 2008 Oct 6;26(31):5088–93.  
8. Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, et al. The role of 
different genetic subtypes of CEBPA mutated AML. Leukemia. 2014 Apr;28(4):794–803.  
9. Hattori T, Ohoka N, Inoue Y, Hayashi H, Onozaki K. C/EBP family transcription factors are 
degraded by the proteasome but stabilized by forming dimer. Oncogene. 2003 Mar 
6;22(9):1273–80.  
10. Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H, et al. Tribbles homolog 2 inactivates 
C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell. 2006 Nov;10(5):401–11.  
11. Keeshan K, Shestova O, Ussin L, Pear WS. Tribbles homolog 2 (Trib2) and HoxA9 cooperate 
to accelerate acute myelogenous leukemia. Blood Cells Mol Dis. 2008 Jan;40(1):119–21.  
12. Rishi L, Hannon M, Salome M, Hasemann M, Frank A-K, Campos J, et al. Regulation of 
Trib2 by an E2F1-C/EBPalpha feedback loop in AML cell proliferation. Blood. 2014 
Feb;123(15):2389–400.  
13. Keeshan K, Bailis W, Dedhia PH, Vega ME, Shestova O, Xu L, et al. Transformation by 
Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood. 
2010 Dec 2;116(23):4948–57.  
14. Mancini E, Sanjuan-Pla A, Luciani L, Moore S, Grover A, Zay A, et al. FOG-1 and GATA-1 
act sequentially to specify definitive megakaryocytic and erythroid progenitors. The EMBO 
Journal. Nature Publishing Group; 2011 Nov 8;:1–15.  
20 
 
15. Ye M, Zhang H, Amabile G, Yang H, Staber PB, Zhang P, et al. C/EBPa controls acquisition 
and maintenance of adult haematopoietic stem cell quiescence. Nat Cell Biol. 2013 
Apr;15(4):385–94.  
16. Hasemann MS, Lauridsen FKB, Waage J, Jakobsen JS, Frank A-K, Schuster MB, et al. 
C/EBPα Is Required for Long-Term Self-Renewal and Lineage Priming of Hematopoietic 
Stem Cells and for the Maintenance of Epigenetic Configurations in Multipotent Progenitors. 
PLoS Genet. 2014 Jan 1;10(1):e1004079–9.  
17. Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, et al. Enhancement 
of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the 
transcription factor C/EBP alpha. Immunity. 2004 Dec;21(6):853–63.  
18. Ohlsson E, Hasemann MS, Willer A, Lauridsen FKB, Rapin N, Jendholm J, et al. Initiation of 
MLL-rearranged AML is dependent on C/EBPα. Journal of Experimental Medicine. 2013 Dec 
23.  
19. Collins C, Wang J, Miao H, Bronstein J, Nawer H, Xu T, et al. C/EBP  is an essential 
collaborator in Hoxa9/Meis1-mediated leukemogenesis. Proceedings of the National Academy 
of Sciences. 2014 Jun 23.  
20. Wagner K, Zhang P, Rosenbauer F, Drescher B, Kobayashi S, Radomska HS, et al. Absence 
of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid 
identity in bcr/abl-induced malignancy. Proc Natl Acad Sci USA. 2006 Apr 18;103(16):6338–
43.  
21. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-
negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha 
(C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001 Mar;27(3):263–70.  
22. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point 
mutations in hematological malignancies. Leukemia. 2005 Mar;19(3):329–34.  
23. Bereshchenko O, Mancini E, Moore S, Bilbao D, Månsson R, Luc S, et al. Hematopoietic 
Stem Cell Expansion Precedes the Generation of Committed Myeloid Leukemia-Initiating 
Cells in C/EBPα Mutant AML. Cancer Cell. Elsevier Ltd; 2009 Nov 3;16(5):390–400.  
24. Quintana-Bustamante O, Smith SL-L, Griessinger E, Reyal Y, Vargaftig J, Lister TA, et al. 
Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis. 
Nature Publishing Group; 2012 Jun 14;26(7):1537–46.  
25. Kirstetter PP, Schuster MBM, Bereshchenko OO, Moore SS, Dvinge HH, Kurz EE, et al. 
Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression 
signature of committed myeloid leukemia-initiating cells. Cancer Cell. 2008 Mar 
31;13(4):299–310.  
26. Yokoyama T, Toki T, Aoki Y, Kanezaki R, Park M-J, Kanno Y, et al. Identification of TRIB1 
R107L gain-of-function mutation in human acute megakaryocytic leukemia. Blood. 2012 
Mar;119(11):2608–11.  
27. Carnicer MJ, Lasa A, Buschbeck M, Serrano E, Carricondo M, Brunet S, et al. K313dup is a 
recurrent CEBPA mutation in de novo acute myeloid leukemia (AML). Ann Hematol. 2008 
Sep 30;87(10):819–27.  
28. Brouwer AJ, Jonker A, Werkhoven P, Kuo E, Li N, Gallastegui N, et al. Peptido Sulfonyl 
21 
 
Fluorides as New Powerful Proteasome Inhibitors. J Med Chem. 2012 Dec 27;55(24):10995–
1003.  
29. Claudia Andreu-Vieyra JRB, Berenson JR. Carfilzomib in multiple myeloma. Expert Opinion 
on Biological Therapy. Informa UK, Ltd; 2014;14 (11 ):000–0.  
30. Grandinetti KB, Stevens TA, Ha S, Salamone RJ, Walker JR, Zhang J, et al. Overexpression 
of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of 
C/EBPalpha. Oncogene; 2011 Mar 14;:1–8.  
31. Wouters BJ, Jorda MA, Keeshan K, Louwers I, Erpelinck-Verschueren CAJ, Tielemans D, et 
al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced 
CEBPA and mutations in NOTCH1. Blood. 2007 Nov 15;110(10):3706–14.  
32. Geletu M, Balkhi MY, Peer Zada AA, Christopeit M, Pulikkan JA, Trivedi AK, et al. Target 
proteins of C/EBP p30 in AML: C/EBP p30 enhances sumoylation of C/EBP p42 via up-
regulation of Ubc9. Blood. 2007 Nov 1;110(9):3301–9.  
33. Pulikkan JA, Dengler V, Zada AAP, Kawasaki A, Geletu M, Pasalic Z, et al. Elevated PIN1 
expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation 
through c-Jun in AML. Leukemia. Oncogene; 2010 Apr 8;24(5):914–23.  
34. Trivedi AK, Bararia D, Christopeit M, PeerZada AA, Singh SM, Kieser A, et al. Proteomic 
identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator 
C/EBPα by inhibiting its ubiquitination. Oncogene. 2006 Sep 18;26(12):1789–801.  
35. Jin G, Yamazaki Y, Takuwa M, Takahara T, Kaneko K, Kuwata T, et al. Trib1 and Evi1 
cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood. 2007 May 1;109(9):3998–
4005.  
36. Xu S, Tong M, Huang J, Zhang Y, Qiao Y, Weng W, et al. TRIB2 inhibits Wnt/beta-
Catenin/TCF4 signaling through its associated ubiquitin E3 ligases, beta-TrCP, COP1 and 
Smurf1, in liver cancer cells. FEBS Letters. 2014 Nov;588(23):4334–41.  
37. Frank R. The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports--
principles and applications. J Immunol Methods. 2002 Sep;267(1):13–26.  
38. Colleran A, Collins PE, O'Carroll C, Ahmed A, Mao X, McManus B, et al. Deubiquitination 
of NF-kappaB by Ubiquitin-Specific Protease-7 promotes transcription. Proc Natl Acad Sci 
USA. 2013 Jan;110(2):618–23.  
 
  
22 
 
Figure Legends 
Figure 1: C/EBPα p42 accelerates AML in the presence of TRIB2 and excess p30 (A) Kaplan-
Meier survival curve of mice reconstituted with either Cebpafl/fl or CebpaΔ/Δ bone marrow 
cells transduced with TRIB2 expressing retrovirus. The median survival of mice reconstituted 
with Cebpafl/fl -TRIB2 cells was 33 weeks (n=12), none of the mice reconstituted with CebpaΔ/Δ-
TRIB2 cells developed leukaemia within 60 weeks (n=10). ***P<0.0001 by Log-rank test. (B) 
Schematic representation of Cebpa alleles (C) Kaplan-Meier survival curve of mice reconstituted with 
either Cebpafl/+ or Cebpafl/p30 bone marrow cells transduced with MigR1 or TRIB2 expressing 
retrovirus. None of the mice reconstituted with Cebpafl/+-MigR1 (n=9) or Cebpafl/p30-MigR1 (n=6) 
developed leukaemia within 60 weeks. The median survival of mice reconstituted with Cebpafl/+-
TRIB2 cells was 49 weeks (n=4), while the median survival of mice reconstituted with Cebpafl/p30-
TRIB2 was 29 weeks (n=8). ***P<0.0001 by Log-rank test. (D) Kaplan-Meier survival curve of mice 
reconstituted with Cebpa∆/p30 bone marrow cells transduced with MigR1 or TRIB2 expressing 
retrovirus. The median survival of mice reconstituted with Cebpa∆/p30-MigR1 cells was 40 weeks 
(n=6), while the median survival of mice reconstituted with Cebpa∆/p30-TRIB2 cells was 35 weeks 
(n=8). P=0.8111 by Log-Rank test. (E) Kaplan-Meier survival curve comparing mice 
reconstituted with Cebpafl/p30-TRIB2 or Cebpa∆/p30-TRIB2 bone marrow cells. *P≤0.05 by 
Log-rank test (F) Average percentage of c-Kit expression in CD45.2+ BM of each group +/- SD (G) 
Protein analysis of C/EBPαp42 and p30 expression in bone marrow of mice. ns=non-specific band. 
Figure 2: Identification of R339 as crucial C/EBPα amino acid in TRIB2 binding (A) Peptide 
arrays encompassing C-terminus of C/EBPα were generated as described in Materials and Methods. 
Eight binding peptides unique to C/EBPα were identified. The table displays the amino acid identity 
of these peptides. This array is representative of two independent SPOT-synthesised arrays. Dark 
spots are indicative of peptide binding. (B) SASSAs on a region spanning the C-terminus of C/EBPα 
were probed with GST-TRIB2. The binding of GST-TRIB2 to each alanine substituted peptide was 
quantified by densitometry and presented as a percentage of the control unmutated WT sequence, 
with an underlay identifying the amino acid which was substituted with an alanine. >50% reduction in 
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binding intensity indicative of involvement in the interaction. (C) Western blot analysis of 293T cell 
lysates expressing WT C/EBPα and C/EBPα mutants (Left panel). GST pull-down, performed in the 
presence of MG132, using GST-TRIB2 followed by Western blot analysis for GST (top and bottom 
panels) and C/EBPα (middle panel).  
Figure 3: Identification of the C/EBPα binding site on TRIB2 (A) Peptide arrays encompassing 
TRIB2 were generated as described in Materials and Methods. Five binding peptides spanning amino 
acids 25-318 of C/EBPα protein were identified. The table displays the amino acid identity of these. 
This array is representative of two independent SPOT-synthesised arrays. Dark spots are indicative of 
peptide binding. (B) SASSAs on regions spanning TRIB2 were probed with C/EBPα protein. The 
binding of C/EBPα protein to each alanine substituted peptide was quantified by densitometry and 
presented as relative intensity of the control unmutated WT sequence, with an underlay identifying 
the amino acid which was substituted with an alanine. >50% reduction in binding intensity indicative 
of involvement in the interaction. (C) 293T lysates expressing WT TRIB2 and mutants R77A, 4-AA 
(S227A/S229A/S231A/K233A) immunoblotted with anti-TRIB2 and actin serving as a loading 
control. (D) TRIB2 binding mutants 4-AA (S227A/S229A/S231A/K233A), R77A and K322A and 
WT C/EBPα were expressed in 293T cells and C/EBPα was immunoprecipitated and lysates were 
immunoblotted for TRIB2 and C/EBPα (top panels). Western blot of total input lysates shows levels 
of protein expression (bottom panels). Densitometric analysis was performed and the ratio of IP:Input, 
normalised to Actin are presented (underneath bottom panels). 
Figure 4: TRIB2 induces binding dependent K48 specific ubiquitin-dependent proteasomal 
degradation of C/EBPα on Lysine K313 (A) 293T cells were transfected with ubiquitin-HA, 
TRIB2, C/EBPα and PHMA empty vector control. Ubiquitination assay was performed. 
Immunoblotting for HA detects ubiquitination (top IP panel), K63 species of polyubiquitination 
(second IP panel), K48 species of polyubiquination (third IP panel) and C/EBPα detects IP protein 
(bottom IP panel). Immunoblotting for TRIB2 and C/EBPα detects input levels and actin serves as a 
loading control (input panels). (B) Ubiquitination assay as outlined in (A) including ubiquitin mutants 
that do not express the K48 (K48R) ubiquitin polychain and the K63 (K63R) ubiquitin polychain. (C) 
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Ubiquitination assay as outlined in (A) including C/EBPα mutants; R339A and R343A. (D) 
Ubiquitination assay as outlined in (A) including TRIB2 binding mutants R77A, 4-AA 
(S227A/S229A/S231/K233A) and K322A. Indicated experiments (B-D) were treated with 10μM MG-
132 for 5hrs before ubiquitination assay was performed. 
Figure 5: TRIB2 ubiquitinates C/EBPα on K313 (A) Ubpred analysis of C/EBPα Ensembl gene ID 
(ENSRNOG00000010918) showing the probability of each Lysine acting as ubiquitination sites. (B) 
Schematic diagram displaying the localisation of K313 in C/EBPα. (C) Ubiquitination assay 
performed with C/EBPα-K313R and TRIB2 in 293T cells. (D) 293T cells were co-transfected with 
the G-CSFR promoter firefly luciferase constructs containing either the C/EBPα WT (WT GCSFR) or 
mutant binding sites (Mut GCSFR), and either an empty PHMA vector or vector containing C/EBPα 
or K313R, along with a pRL-TK Renilla luciferase internal control plasmid. Luciferase activity was 
measured 24 hours post-transfection. Bar chart represents reporter luciferase activity for each sample 
normalised for renilla values, and graphed relative to the control sample. Results analysed using two-
tailed unpaired t-test and representative of 3 independent experiments. (E) Ubiquitination assay 
performed with C/EBPα p30 and TRIB2 in 293T cells. 
Figure 6: Modulation of TRIB2 levels sensitizes AML cells to cell death induced by proteasome 
inhibition (A) Sorted GFP+ cells transduced with MigR1 control, MigR1-TRIB2, MigR1-VPM or 
MigR1-C/EBPα retrovirus were treated +/- 10nM bortezomib for 16-24hrs and analysed by flow 
cytometry for cell death by DAPI. Graph of fold change in cell death as determined by DAPI positive 
cells. Data displayed is average of 3 technical replicates, and is representative of 2 independent 
experiments. (ns denotes not significant, *P<0.05,**P<0.005 by Student´s unpaired t test). (B) Sorted 
GFP+ U937 cells transduced with either Phr or Phr-TRIB2 were treated with 10nM bortezomib, 
500nM sulfonyl fluoride (SF), 10nM carfilzomib (Cfz) or DMSO only for 16hrs. Cytotoxicity was 
assessed by Dapi staining. Representative FACS plots of 3 independent experiments with 2 technical 
replicates each are shown. (C) Sorted GFP+ U937 cells transduced with either Phr or Phr-TRIB2 were 
treated for 6 and 8h with 10nM bortezomib or DMSO only (NDC, no drug control) and cell lysates 
were analysed for C/EBPα expression by Western blotting. TRIB2 overexpression was confirmed and 
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tubulin was used as loading control. Representative of 2 independent experiments. (D) Schematic 
representation of the AML xenograft study. NOD-SCID IL2Rγnull mice (NSG) were transplanted with 
GFP+hCD45+ U937 cells (n=6). Each group was randomized into 2 groups for treatment with 
0.5mg/kg bortezomib or PBS, i.p., on a regime schedule of 3 injections for 16 days. (E) TRIB2 gene 
knockdown was confirmed at the mRNA level in shTRIB2-U937 cells selected with 2μg/ml 
puromycin for 48h. Values represent gene expression relative to shctrl-U937 cells and normalized to 
the reference gene ABL (***P<0.001 by Student´s t test). (F) GFP and hCD45 expression in BM were 
quantified by flow cytometry as a measure of disease burden in control PBS (n=3) and bortezomib 
(n=3) treated animals and data are shown by representative FACS contour plots (lower panel) and bar 
graphs (upper panel) with means ± SD (*P<0.05 by Student´s t test). (G) GFP and hCD45 expression 
in BM were quantified by flow cytometry as a measure of disease burden in shctrl (n=5) and shTRIB2 
U937 (n=8) mice and data are shown by representative FACS contour plots (lower panel) and bar 
graphs (upper panel) with means ± SD (***P<0.001 by Student´s t test).   
 






